<span item_type="fundamental" item_id="6845dfbbe174fd97244b550a47033fe1" counter_id="ST/US/FTII" env="prod"></span><span item_type="announcement" item_id="552357503601216001" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -0.04.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues as of June 30, 2025, as it is still in the process of identifying a target company for a business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended June 30, 2025, the net loss was - $80,647, compared to - $44,457 for the same period in 2024. For the six months ended June 30, 2025, the net loss was - $370,320, compared to a net income of $85,119 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li><strong>Total Expenses</strong>: For the three months ended June 30, 2025, total expenses were $138,735, compared to $284,894 for the same period in 2024. For the six months ended June 30, 2025, total expenses were $592,572, compared to $595,828 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: For the six months ended June 30, 2025, net cash used in operating activities was - $1,187,204, compared to - $591,410 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li><strong>Investing Cash Flow</strong>: For the six months ended June 30, 2025, net cash provided by investing activities was $17,585,764, compared to $36,123,240 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li><strong>Financing Cash Flow</strong>: For the six months ended June 30, 2025, net cash used in financing activities was - $16,294,605, compared to - $35,548,932 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Interest Income</strong>: For the three months ended June 30, 2025, interest income was $72,477, compared to $283,084 for the same period in 2024. For the six months ended June 30, 2025, interest income was $272,304, compared to $819,427 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on completing its initial business combination, specifically the proposed merger with Longevity Biomedical, Inc. The merger is expected to result in the company changing its name to Longevity Biomedical, Inc. and listing its common stock on the NASDAQ Capital Market under the ticker symbol ‘LBIO’.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company has entered into a Subscription Agreement with an investor for a private placement of 1,000,000 shares of Class A Common Stock at $5.00 per share, contingent upon the consummation of the business combination with Longevity.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li><li><strong>Priority</strong>: The company has until August 18, 2025, to complete a business combination, with the possibility of extending the deadline to August 18, 2026, through monthly extensions, provided certain conditions are met.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1889450/000164117225025250/form10-q.htm"></span></li></ul>

FutureTech II Acquisition | 10-Q: FY2025 Q2 EPS: USD -0.04